Natera

Medical Director - Reproductive Endocrinology and Infertility - IVF Services

United States

Natera Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
InternshipJob Type
UnknownVisa
Healthcare, Reproductive Medicine, Genetic TestingIndustries

Requirements

Candidates must possess a Medical Degree (M.D. or D.O.) and be board-certified in Reproductive Endocrinology and Infertility, along with at least five years of experience within the IVF space, preferably including clinical research and development. They should also have knowledge and experience with clinical genetics and IVF-related practice guidelines.

Responsibilities

The Medical Director will represent Natera with clinicians, academic institutions, and healthcare organizations, provide scientific and clinical presentations on Natera’s reproductive genetic products, collaborate with MSLs and Clinical Services teams to manage product quality, serve as a medical and scientific resource for sales and marketing teams, develop and maintain relationships with KOLs, address customer inquiries, oversee case-related issues, provide feedback on educational materials, collaborate on clinical development with R&D teams, and complete required training on HIPAA/PHI privacy, compliance, and security. The role also involves travel up to 60% and passing a post-offer criminal background check.

Skills

Reproductive Endocrinology
Infertility
Clinical Research
Medical Education
Healthcare Collaboration
Public Speaking
Product Knowledge
KOL Management
HIPAA/PHI Privacy

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Key Metrics

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI